title: Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer.
abstract: Recent studies have indicated that chemotherapy not only provides some survival benefit, but also reduces tumor-related symptoms and improves the performance status of patients receiving chemotherapy. Data from single-agent gemcitabine studies demonstrate improvements in a range of tumor symptoms, including cough, hemoptysis, pain, dyspnea, and anorexia, as well as increases in performance status. Indeed, more patients benefit from gemcitabine chemotherapy than suggested by the objective response rate. Surveys also have shown that patients are much more likely to accept chemotherapy for what is perceived by health care professionals as potentially small benefits. Gemcitabine has a role in the palliative treatment of patients with advanced non-small cell lung cancer.
authors.affiliation: CRC Department of Medical Oncology, Christie and Wythenshawe Hospitals, Manchester, England.
authors.forename: N
authors.initials: N
authors.lastname: Thatcher
authors.forename: G
authors.initials: G
authors.lastname: Jayson
authors.forename: B
authors.initials: B
authors.lastname: Bradley
authors.forename: M
authors.initials: M
authors.lastname: Ranson
authors.forename: H
authors.initials: H
authors.lastname: Anderson
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D012264:Ribonucleotide Reductases; D000093542:Gemcitabine